Literature DB >> 2789654

Dry eyes or mouth--an epidemiological study in Swedish adults, with special reference to primary Sjögren's syndrome.

L T Jacobsson1, T E Axell, B U Hansen, V J Henricsson, A Larsson, K Lieberkind, B Lilja, R Manthorpe.   

Abstract

The prevalence of dry eyes or dry mouth, and of primary Sjögren's syndrome (primary SS) according to the Copenhagen criteria were established in 705 randomly selected subjects, aged 52-72 years who answered a simple questionnaire, and of whom 247 (35%) reported symptoms. A subgroup with symptoms (n = 77) and a matched asymptomatic control group (n = 32) were examined with the Schimer-1 test (S1t), tear film break-up time (BUT), van Bijsterveld score (vB), unstimulated whole sialometry (Sialo) and, in about 40% of them labial salivary gland (LSG) biopsy and salivary gland scintigraphy. Apart from four cases of keratoconjunctivitis sicca (KCS) among controls, cases of KCS (15), xerostomia (12), autoimmune sialoadenitis (6) and primary SS (6) were exclusively confined to the symtomatic group. The calculated frequencies (with 95% confidence intervals) for the whole population were 14.9 (7.3-22.6)% for KCS, 5.5(3.0-7.9)% for xerostomia and 2.7 (1.0-4.5)% for autoimmune sialoadenitis and primary SS. The serum levels of ANA and RF were similar in the two groups, though those of anti-SS-B/La antibodies were higher in the group with symptoms (P less than 0.01).

Entities:  

Mesh:

Year:  1989        PMID: 2789654     DOI: 10.1016/0896-8411(89)90185-6

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  20 in total

1.  Sicca symptoms, saliva and tear production, and disease variables in 636 patients with rheumatoid arthritis.

Authors:  T Uhlig; T K Kvien; J L Jensen; T Axéll
Journal:  Ann Rheum Dis       Date:  1999-07       Impact factor: 19.103

2.  Prevalence of Sjögren's syndrome in a closed rural community.

Authors:  U G Dafni; A G Tzioufas; P Staikos; F N Skopouli; H M Moutsopoulos
Journal:  Ann Rheum Dis       Date:  1997-09       Impact factor: 19.103

3.  Acetylcholine-evoked calcium mobilization and ion channel activation in human labial gland acinar cells from patients with primary Sjögren's syndrome.

Authors:  L J Dawson; E A Field; A R Harmer; P M Smith
Journal:  Clin Exp Immunol       Date:  2001-06       Impact factor: 4.330

4.  Sicca symptoms and secondary Sjögren's syndrome in systemic lupus erythematosus: comparison with rheumatoid arthritis and correlation with disease variables.

Authors:  I M Gilboe; T K Kvien; T Uhlig; G Husby
Journal:  Ann Rheum Dis       Date:  2001-12       Impact factor: 19.103

5.  Abnormal regional cerebral blood flow on 99mTc ECD brain SPECT in patients with primary Sjögren's syndrome and normal findings on brain magnetic resonance imaging.

Authors:  C P Chang; Y C Shiau; J J Wang; S T Ho; A Kao
Journal:  Ann Rheum Dis       Date:  2002-09       Impact factor: 19.103

Review 6.  [Pathogenesis and diagnosis of Sjögren's syndrome].

Authors:  T Witte
Journal:  Z Rheumatol       Date:  2010-02       Impact factor: 1.372

Review 7.  Sjögren's syndrome in older patients: aetiology, diagnosis and management.

Authors:  Rada V Moerman; Hendrika Bootsma; Frans G M Kroese; Arjan Vissink
Journal:  Drugs Aging       Date:  2013-03       Impact factor: 3.923

8.  Clinical profiles of non dry eye patients and correlations with tear protein levels.

Authors:  C Snyder; R J Fullard
Journal:  Int Ophthalmol       Date:  1991-11       Impact factor: 2.031

9.  Use of the European preliminary criteria, the Breiman-classification tree and the American-European criteria for diagnosis of primary Sjögren's Syndrome in daily practice: a retrospective analysis.

Authors:  C Langegger; M Wenger; C Duftner; C Dejaco; I Baldissera; R Moncayo; M Schirmer
Journal:  Rheumatol Int       Date:  2007-01-25       Impact factor: 3.580

10.  Acute Inhibitory Effects of Antidepressants on Lacrimal Gland Secretion in the Anesthetized Rat.

Authors:  Martin Dankis; Ozgu Aydogdu; Gunnar Tobin; Michael Winder
Journal:  Invest Ophthalmol Vis Sci       Date:  2021-06-01       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.